<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thirty-one patients (median age, 44 years) with advanced <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> were given thiotepa 15 mg/kg, and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 120 (n = 14) or 150 (n = 17) mg/kg followed by unfractionated peripheral blood stem cell transplants (PBSCT) from genotypically identical siblings (n = 28) or one antigen mismatched family donor (n = 3) </plain></SENT>
<SENT sid="1" pm="."><plain>Donors were mobilized with granulocyte colony-stimulating factor 5 to 10 microgram/kg/d for 6 days and underwent two to three leukapheresis on days +5, +6, +7 </plain></SENT>
<SENT sid="2" pm="."><plain>The median cell yield per donor expressed/kg of recipients body weight was as follows: nucleated cells 13 x 10(8)/kg; CD34+ cells 6 x 10(6)/kg; colony-forming unit-granulocyte macrophage 38 x 10(4)/kg, and CD3+ cells 449 x 10(6)/kg </plain></SENT>
<SENT sid="3" pm="."><plain>The diagnoses were <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n = 4), <z:hpo ids='HP_0011009'>acute</z:hpo> myeloid (n = 9) or <z:hpo ids='HP_0005526'>lymphoid leukemia</z:hpo> (n = 2), <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> (n = 2), <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (n = 1), <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 6), <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (n = 1) <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (n = 6) </plain></SENT>
<SENT sid="4" pm="."><plain>Twenty-eight patients had advanced disease, 29 patients were first grafts, and 2 were second transplants 3 and 9 years after the first </plain></SENT>
<SENT sid="5" pm="."><plain>Neutrophil counts of 0.5 x 10(9)/L and platelet counts of 30 x 10(9)/L platelets were both achieved on day +14 (median) </plain></SENT>
<SENT sid="6" pm="."><plain>Engraftment could be proven by sex markers or DNA polymorphism in 29 of 31 patients: one had early <z:hpo ids='HP_0001909'>leukemia</z:hpo> relapse and one patient was unevaluable because of early <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) was scored as minimal or absent (grade 0 to 1) in 14 patients, moderate (grade II) in 13, and severe (grade III to IV) in four </plain></SENT>
<SENT sid="8" pm="."><plain>Causes of <z:hpo ids='HP_0011420'>death</z:hpo> were <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n = 4), <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD (n = 4, with associated <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">cytomegalovirus infections</z:e> in three), <z:hpo ids='HP_0100806'>sepsis</z:hpo> (n = 1), <z:hpo ids='HP_0001399'>liver failure</z:hpo> (n = 1), multiorgan failure (n = 1), and <z:mp ids='MP_0001914'>hemorrhage</z:mp> (n = 1) </plain></SENT>
<SENT sid="9" pm="."><plain>The actuarial transplant mortality is 29%, the actuarial relapse rate 22% </plain></SENT>
<SENT sid="10" pm="."><plain>Nineteen patients survive with a median follow up of 288 days (100-690) </plain></SENT>
<SENT sid="11" pm="."><plain>The actuarial 2-year survival is 57% </plain></SENT>
<SENT sid="12" pm="."><plain>Three patients received PBSCT from family donors mismatched for one class II antigen: <z:hpo ids='HP_0000001'>all</z:hpo> engrafted, one developed grade I aGVHD; one died of <z:hpo ids='HP_0001909'>leukemia</z:hpo> on day +155; two are alive disease free 267 to 290 days postgraft </plain></SENT>
<SENT sid="13" pm="."><plain>This study suggests that thiotepa <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> followed by unfractionated PBSC allograft may be an alternative form of transplant for adults with advanced <z:hpo ids='HP_0001909'>leukemia</z:hpo>, also in the setting of one antigen mismatched donor </plain></SENT>
<SENT sid="14" pm="."><plain>The engraftment is rapid with acceptable GVHD and relatively low transplant-related mortality </plain></SENT>
</text></document>